Colorectal Cancer (CRC) Cetuximab Elderly Frail

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC) prolongs Progression Free Survival, compared with 5-fluorouracil alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors

NCT01858662

Metastatic Colorectal Cancer

TERMINATED PHASE2

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

NCT00077233

Colorectal Cancer

TERMINATED PHASE3

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

NCT01276379

Colorectal Cancer

COMPLETED PHASE2

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

NCT01134666

Colorectal Neoplasms

TERMINATED

Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.

NCT01068132

Colorectal Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary efficacy analyses will be performed on the Intention-to-treat population.

The safety analyses will be performed on the Safety population.

* Median PFS and OS in each treatment arm with its 95% CI, estimated by the Kaplan-Meier technique
* Response rates by treatment arm with their exact 95% CI
* IADL sum score, G8 sum score and social situation by treatment arm at baseline and at each timepoint of assessment
* QoL scores from the EORTC QLQ-C30 and QLQ-ELD14 modules by treatment arm at baseline and at each timepoint of assessment
* Safety data by treatment arm in the Safety population. Worst toxicity grade over all cycles according to the CTCAE criteria version 4.0 by treatment arm.
* Pharmaco-economics evaluation

Summary of proposed Phase II trial characteristics:

1. Total number of randomized patients: 150.
2. Total number of events at phase II analysis for primary endpoint: 110.
3. Total number of patients screened over the phase II: 250.
4. Total number of patients treated with cetuximab for the Phase II study: 75.
5. Maximum study duration: 19 months.

In the present study, HRQoL is an important secondary endpoint. The objective of the HRQoL data collection in this Phase II trial is to assess the impact of the addition of cetuximab on patients' HRQoL during treatment.

The hypothesis is that there will be no difference in patients' HRQoL between both treatment arms during treatment. The HRQoL domains (from the EORTC QLQ-C30 module) which are expected to be affected by treatment (to the same extent in both arms) are Global health status, Fatigue, Pain and Stool habits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Metastatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5-fluorouracil/leucovorin plus cetuximab

Group Type EXPERIMENTAL

Cetuximab

Intervention Type DRUG

500 mg/m2 on day 1, Every 14 days Intravenously

5-fluorouracil

Intervention Type DRUG

Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously

leucovorin

Intervention Type DRUG

Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously

5-fluorouracil/leucovorin alone

Group Type ACTIVE_COMPARATOR

5-fluorouracil

Intervention Type DRUG

Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously

leucovorin

Intervention Type DRUG

Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cetuximab

500 mg/m2 on day 1, Every 14 days Intravenously

Intervention Type DRUG

5-fluorouracil

Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously

Intervention Type DRUG

leucovorin

Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Erbitux 5-FU Folinic Acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathologically confirmed metastatic colorectal cancer
* Measurable disease according to RECIST V1.1
* Histological local review and analysis of KRAS
* Age ≥ 80 or ≥ 70 in combination with functional restrictions defined as limitation in at least 2 of 8 IADL
* WHO performance status 0, 1 or 2
* Adequate bone marrow reserves, hepatic function \& renal function
* Normal 12 lead ECG without clinically significant abnormalities
* Written informed consent before randomization according to ICH/EU GCP, and local, national and international regulations

Exclusion Criteria

* Prior systemic chemotherapy for metastatic disease
* Previous exposure to EGFR or VEGF/VEGFR targeted therapy
* Patients may have received chemotherapy in the adjuvant or neoadjuvant setting (CRC). The treatment-free interval should be 6 months or more from the end of (neo-)adjuvant therapy
* Previous radiotherapy, either in the adjuvant setting or for the treatment of bone metastases, is allowed provided that the measurable lesions are outside the radiation fields
* Persistence of clinically relevant treatment-related toxicities from previous chemotherapy and/or radiotherapy (adjuvant or neo-adjuvant setting)
* Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of treatment or concomitantly with this trial
* Known alcohol or drug abuse
* Clinically significant cardiovascular disease
* Evidence of uncontrolled medical comorbidities despite adequate treatment
* Patients who have suffered a cerebrovascular accident or transient ischemic attack within the past 12 months
* History, within the past 5 years, of malignancies other than CRC
* Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and followup schedule

Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No